Skip Nav Destination
1-20 of 73
Published Online: 18 October 2023
...Husein Husein-ElAhmed; Sara Husein-ElAhmed Background: Lichen planopilaris (LPP) is a primary chronic lymphocytic cutaneous disorder that selectively destroys the hair follicles, resulting in scarring alopecia. Unfortunately, current available treatments are not fully effective to stop hair loss...
Fen Wei, Li Li, Yi Kong, Xiaofeng Yan, Kevin J. Varghese, Song Zhang, Jian Jiang, Bao Chai, Hongxiang Chen
Published Online: 17 October 2023
..., and clinical treatment recommendations for Demodex -associated rosacea, with the ultimate goal of improving patient outcomes. firstname.lastname@example.org email@example.com 25 07 2022 18 09 2023 17 10 2023 © 2023 S. Karger AG, Basel Copyright / Drug Dosage / Disclaimer...
Yora Mostmans, Bertrand Richert, Viviane De Maertelaer, Ines Saidi, Asma Benslimane, Thao Tran Thi Thanh, Francis Corazza, Olivier Michel
Published Online: 25 August 2023
... Northern Europe. The relatively high rate of CSU patients receiving oral glucocorticosteroid treatment for their disease though not always classified as severe, underlines the need to train doctors of various specialties in the treatment algorithms of CSU. Furthermore, by looking at potential autoimmune...
Dermatology (2023) 239 (4): 553–564.
Published Online: 08 August 2023
... responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2023 Primary cutaneous lymphoma Incidence Clinical features Prognosis Treatment Primary cutaneous lymphomas (PCL), including cutaneous...
Kelsey R. van Straalen, Thrasyvoulos Tzellos, Afsaneh Alavi, Farida Benhadou, Carlos Cuenca-Barrales, Mathilde Daxhelet, Mathieu Daoud, Ourania Efthymiou, Evangelos J. Giamarellos-Bourboulis, Philippe Guillem, Wayne Gulliver, Gregor B.E. Jemec, Alexander Katoulis, Anke Koenig, Elizabeth Lazaridou, Michelle A. Lowes, Angelo V. Marzano, Lukasz Matusiak, Alejandro Molina-Leyva, Chiara Moltrasio, Andreas Pinter, Concetta Potenza, Errol P. Prens, Jorge Romaní, Ditte M. Saunte, Christopher Sayed, Nevena Skroza, Dimitra Stergianou, Jacek C. Szepietowski, Anastasia Trigoni, Eva Vilarrasa, Athanassios Kyrgidis, Christos C. Zouboulis, Hessel H. van der Zee
Dermatology (2023) 239 (3): 362–367.
Published Online: 13 June 2023
... validation is an important aspect of clinical outcomes. Objectives: We aimed to externally validate the novel dichotomous IHS4-55 in a non-biologic treated dataset of HS patients. Methods: Data from a previously published European-wide prospective clinical study of antibiotic treatment of HS patients were...
Anne Sofie Frølunde, Malthe Alexander Knudsgaard Wiis, Hakim Ben Abdallah, Stine Elsgaard, Anna Kathrine Danielsen, Mette Deleuran, Christian Vestergaard
Dermatology (2022) 238 (5): 950–960.
Published Online: 13 April 2022
... concerning effect of treatment for non-atopic CNPG. Due to few randomized controlled trials (RCTs) and case series, the literature was unfortunately too sparse to conduct a meta-analysis of the results. Instead, we thoroughly report important data from the three existing RCTs and 6 case studies with more...
Dermatology (2022) 238 (4): 807–810.
Published Online: 29 December 2021
... measures reduce the likelihood of developing CIAE and decrease its severity, making it easier to treat if it were to occur. Ongoing research on the treatment of CIAE continues. Of these treatments, oral tetracyclines and systemic corticosteroids have been shown to be the most effective by far...
Fatma Jendoubi, Stefana Balica, Marie Aleth Richard, Christine Chiaverini, Claire Bernier, Nathalie Quiles, Herve Bachelez, Marie Beylot-Barry, Stéphanie Mallet, Catherine Goujon, Josiane Parier, Laurent Misery, Florence Carrere, Valérie Lauwers-Cances, Carle Paul, for the French Psoriasis Research Group
Dermatology (2022) 238 (4): 630–639.
Published Online: 09 December 2021
... was stratified by previous treatment history. The primary outcome was HRQoL, assessed by scoring the Skindex-29 domains emotion, symptom, and functioning. Psoriasis severity was assessed using the psoriasis area severity index (PASI). Levels of perceived stress, patient knowledge about psoriasis, and patient...
Dermatology (2022) 238 (4): 615–619.
Published Online: 12 November 2021
...-center cohort study was established to evaluate efficacy and safety of tildrakizumab in daily practice. Methods: Following approval of tildrakizumab, patients with moderate-to-severe plaque psoriasis eligible for systemic treatment were included into the Kiel Tildra Cohort (KTC) and followed using...
Christoph Blazejak, Rene Stranzenbach, Janika Gosman, Thilo Gambichler, Ulrike Wehkamp, Sarja Stendel, Claus-Detlev Klemke, Marion Wobser, Joanna Olk, Jan P. Nicolay, Maria Weyermann, Rudolf Stadler, Chalid Assaf
Dermatology (2022) 238 (3): 498–506.
Published Online: 02 September 2021
.... The median time of PFS was 12 months and median time to next treatment was 7 months. Only 3/63 patients showed serious side effects, e.g., port infection or acute renal failure. Almost 73% of the patients experienced minor to moderate side effects (CTCAE grade 0–2). Fatigue (27.2%), fever (22.7%), and mild...
Vanessa Lin, Raahi Patel, Alexis Wirtz, Deepika Mannem, Ryan Ottwell, Wade Arthur, Courtney Cook, Hannah Howard, Drew Wright, Micah Hartwell, Matt Vassar
Dermatology (2021) 237 (4): 496–505.
Published Online: 17 May 2021
... from multiple fields of medicine. Objectives: This study’s primary objective was to evaluate the abstracts of systematic reviews and meta-analyses focused on the treatment of atopic dermatitis for the nine most severe forms of spin. Methods: We systematically searched Embase and MEDLINE for systematic...
Dermatology (2022) 238 (1): 167–169.
Published Online: 23 April 2021
...Brent J. Doolan; Michelle Weaich; Joanne Mamo; Monisha Gupta Autologous non-cultured epidermal cellular grafting is the treatment of choice for patients with stable refractory vitiligo. Recently, studies have shown cost-effective alternatives for this procedure, superseding previous techniques...
Sven van Egmond, Loes M. Hollestein, Carin A. Uyl-de Groot, Judith A. van Erkelens, Marlies Wakkee, Tamar E.C. Nijsten
Dermatology (2021) 237 (6): 1000–1006.
Published Online: 27 January 2021
... (Vektis) in the Netherlands. Results: For over 220,000 patients, a skin cancer diagnosis-related group was reimbursed in 124 healthcare centres. Conventional excision reflected 75% of treatments for skin cancer but showed large variation between practices. Large practice variation was also found for 5...
Andreas Pinter, Mana Sarlak, Kim Nicola Zeiner, Bartosz Malisiewicz, Roland Kaufmann, Marco Romanelli, Anke Koenig, Andrea Chiricozzi
Dermatology (2021) 237 (5): 759–768.
Published Online: 16 December 2020
... in patients with a coprevalence of both diseases. Hidradenitis suppurativa Psoriasis Prevalence Comorbidity Treatment Adalimumab Depression Obesity The prevalence of psoriasis in the European adult population is approximately 2–2.5%, whereas the prevalence data for hidradenitis...
Dermatology (2021) 237 (6): 907–911.
Published Online: 22 October 2020
..., and none of the patients showed extrafacial lesions. There seems to be a possibility that treatment duration may be associated with the treatment response. Conclusions: This study confirms clinical characteristics of GR based on the diagnosis combining both clinical and histological findings. daehun...
Dermatology (2021) 237 (5): 771–785.
Published Online: 18 September 2020
... treatment for mild forms and narrow-band ultraviolet (NB-UVB) phototherapy as a second-line option. In severe psoriasis, cyclosporine and biologics may be considered as third-line options, carefully weighing the benefits and risks. Among biologics, certolizumab (approved only for psoriatic arthritis) has...
Dermatology (2020) 236 (4): 289–295.
Published Online: 01 November 2019
.... Hidradenitis suppurativa Acne inversa Dietary changes Diet Dairy Nightshades Treatment Management Research Article Dermatology 2020;236:289 295 DOI: 10.1159/000503063 Received: July 15, 2019 Accepted after revision: August 29, 2019 Published online: November 1, 2019 Prevalence and Impact of Dietary...
Dermatology (2021) 237 (1): 81–96.
Published Online: 23 October 2019
... grown over recent years, our understanding of HS pathogenesis and optimal treatment approaches continues to evolve. Nine HS treatment guidelines developed by various expert organizations have been published, encompassing therapeutic modalities ranging from topical agents to systemic therapies...
Christos C. Zouboulis, Hendrik Hansen, Raffaele Dante Caposiena Caro, Giovanni Damiani, Isabelle Delorme, José Carlos Pascual, Ziad Reguiai, Anastasia Trigoni, Eva Vilarrasa, Fernando Alfageme Roldán
Dermatology (2020) 236 (1): 25–30.
Published Online: 18 October 2019
...Christos C. Zouboulis; Hendrik Hansen; Raffaele Dante Caposiena Caro; Giovanni Damiani; Isabelle Delorme; José Carlos Pascual; Ziad Reguiai; Anastasia Trigoni; Eva Vilarrasa; Fernando Alfageme Roldán Background: Adalimumab is the only approved compound for the treatment of adult patients...
Dermatology (2019) 235 (5): 434–439.
Published Online: 11 July 2019
... is then required, not only for a correct diagnosis and epidemiological data, but also for planning the appropriate treatment. Trichophyton violaceum Tinea capitis Tinea corporis Onychomycosis Dermatophytosis Treatment Terbinafine Griseofulvine Research Article Dermatology 2019;235:434 439 DOI...